The DEBATE Study "DEvelopment of Endotype-based Biomarkers for the monitoring of Greek pATiEnts with CRSwNP" - DEBATE

Inclusion Criteria

• Inclusion Criteria:
• - Age ≥ 18 years
• - If CRSwNP group:
• Physician-diagnosed severe, uncontrolled CRSwNP according to the EUFOREA/EPOS 2020 and ICAR-RS 2021 guidelines with:
• • CRSwNP severity consistent with the need for surgery as defined by a total nasal polyp score (NPS) of ≥5 (≥2 for each nostril)
• • Nasal Congestion Score (NCS) of ≥2
• • Ongoing documented symptoms of CRSwNP for > 8 weeks before surgery
• If CRSsNP group:
• Diagnosis of CRSsNP according to the EUFOREA/EPOS 2020 and ICAR-RS 2021 guidelines
• - Have performed in the period between 2012 and enrolment or are scheduled to perform endoscopic sinus surgery (ESS) for the first time at enrolment
• - Have available nasal polyp tissue sample from the first endoscopic sinus surgery (ESS)
• - Have provided signed and dated written informed consent
• - If CRSwNP group:
• Patients receiving any standard of care treatment for CRSwNP, provided the participant is stable on that treatment for ≥30 days
• Exclusion Criteria:
• - Patients with cystic fibrosis or immunodeficiency
• - Presence of acute exacerbation of CRS symptoms within 2 weeks prior to surgery
• - Use of systemic corticosteroids within 30 days prior to surgery, or antileukotrienes within 15 days prior to surgery, or biologic therapy prior to surgery
• - Not adequate amount (<0.15g) or quality (e.g. storage temperature, contamination) of tissue sample for analyses
• - Not available blood (serum) sample, only for patients scheduled to perform endoscopic sinus surgery (ESS) for the first time at the date of enrolment, for analyses.